SGLT2 저해제/metformin 고정용량복합제의 국내 사용 현황
Use of SGLT2 inhibitor/metformin fixed dose combination in Korea
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in combination with metformin. Methods: Type 2 diabetes patients on SGLT2i/metformin combination therapy were extracted from the 2019 Health Insurance Review & Assessment ServiceNational Patients Sample. On July 1, 2019, SGLT2i and metformin fixed-dose combination (SGLT2i/metformin FDC) and two-pill combination (TPC) groups were identified, and a chi-square test and multiple logistic regression were performed. Results: Of total 2,992 patients, 1,077 (36%) were prescribed SGLT2i/metformin FDC and 1,915 (64%) were prescribed TPC. We found that the most common comorbidities were in the order of dyslipidemia, gastrointestinal disease, and hypertension. Multiple logistic regression analysis showed that the use of SGLT2i/metformin FDC was lower than TPC in patients with diabetic neuropathy (OR=0.76, p=0.008). Clinic (OR=2.09, p
Abstract
Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in combination with metformin. Methods: Type 2 diabetes patients on SGLT2i/metformin combination therapy were extracted from the 2019 Health Insurance Review & Assessment ServiceNational Patients Sample. On July 1, 2019, SGLT2i and metformin fixed-dose combination (SGLT2i/metformin FDC) and two-pill combination (TPC) groups were identified, and a chi-square test and multiple logistic regression were performed. Results: Of total 2,992 patients, 1,077 (36%) were prescribed SGLT2i/metformin FDC and 1,915 (64%) were prescribed TPC. We found that the most common comorbidities were in the order of dyslipidemia, gastrointestinal disease, and hypertension. Multiple logistic regression analysis showed that the use of SGLT2i/metformin FDC was lower than TPC in patients with diabetic neuropathy (OR=0.76, p=0.008). Clinic (OR=2.09, p
참고문헌 (34)
- "Diabetes: ≥30 years 2021"[URL]
- Wild S, "Global prevalence of diabetes : estimates for the year 2000 and projections for 2030", Diabetes Care, 27(5), pp.1047~1053 (2004)
- Danaei G, "National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980:systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants", Lancet, 378(9785), pp.31~40 (2011)
- "Clinical practice guidelines for diabetes 2021"[URL]
- American Diabetes Association, "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021", Diabetes Care, 44(1), pp.S111~S124 (2020), American Diabetes Association[DOI]
- Ko SH, "Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide populationbased cohort study", Medicine(Baltimore), 95(27), pp.e4018~ (2016)
- Fujita Y, "Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes : Clinical data and mechanism of action", J Diabetes Investig, 5(3), pp.265~275 (2014)
- "Medicines integrated information system"[URL]
- American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019", Diabetes care, 42(Suppl. 1), pp.S90~S102 (2019)
- Huang ES, "The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients : the diabetes and aging study", J Gen Intern Med, 25(2), pp.141~146 (2010)
- Blüher M, "Pill burden in patients with type 2 diabetes in Germany: Subanalysis from the prospective, noninterventional PROVIL study", Clin Diabetes, 33(2), pp.55~61 (2015)
- Donnan PT, "Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes : a retrospective cohort study", Diabet Med, 19(4), pp.279~284 (2002)
- Baumgartner A, "Does the polypill improve patient adherence compared to its individual formulations? A systematic review", Pharmaceutics, 12(2), pp.190~ (2020)
- Bell DS, "Combine and conquer : advantages and disadvantages of fixed-dose combination therapy", Diabetes Obes Metab, 15(4), pp.291~300 (2013)
- Zonszein J, "Strategies for Diabetes Management : Using Newer Oral Combination Therapies Early in the Disease", Diabetes Ther, 7(4), pp.621~639 (2016)
- Lingvay I, "Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes", Postgrad Med, 132(4), pp.337~345 (2020)
- Han S, "Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens : a meta-analysis", Curr Med Res Opin, 28(6), pp.969~977 (2012)
- Blonde L, "Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide", metformin tablets as compared to glyburide co-administered with metformin, 2003, pp.5(6), 424~431
- HU J, "Empagliflozin", metformin fixed-dose combination : a review in patients with type 2 diabetes, 2016, pp.17(18), 2471~2477
- Benford M, "Fixed-dose combination antidiabetic therapy : real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance", Adv Ther, 29(1), pp.26~40 (2012)
- Kim J, "National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2diabetes mellitus", Eur J Clin Pharmacol, 75(12), pp.1723~1730 (2019)
- Kaur KK, "Role of combination therapy with SGLT2 Inhibitor with metformin as initial treatment for type2diabetes-advantages of oral fixed drug pill like empagliflozin", metformin in patients with cardiovascular and renal risk-A short communication, 2019, pp.2(1), 15~19
- "Healthcare Bigdata Hub"[URL]
- Schipf S, "Regional differences in the prevalence of known Type 2 diabetes mellitus in 45-74 years old individuals : results from six population-based studies in Germany(DIAB-CORE Consortium)", Diabet Med, 29(7), pp.88~95 (2012)
- Valov V, "Regional differences in diabetic patients’ pharmacotherapy in Bulgaria", Eur Rev Med Pharmacol Sci, 18(10), pp.1499~1506 (2014)
- 오주아, "우리나라 프로톤펌프저해제 사용 양상에 대한 연구: 2016-2020 보건의료빅데이터개방시스템 데이터를 이용한 분석", 약 학 회 지, 65(4), pp.276~283 (2021), 대한약학회[DOI]
- "2019 Drug reimbursement adequacy evaluation result"[URL]
- "Number of doctors employed in medical institutions per 1,000 population"[URL]
- Frias JP, "Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes", Expert Rev Endocrinol Metab, 14(2), pp.75~83 (2019)
- Hutchins V, "A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes", Curr Med Res Opin, 27(6), pp.1157~1168 (2011)
- [URL]
- 박지혜, "제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구", 한국임상약학회지, 24(3), pp.193~198 (2014), 한국임상약학회
- Böhm AK, "Regimen simplification and medication adherence : Fixed-dose versus loosedose combination therapy for type 2 diabetes", PLoS One, 16(5), pp.e0250993~ (2021)
- Moriarty F, "Fixed-dose combination antihypertensives and risk of medication errors", Heart, 105(3), pp.204~209 (2019)